Format
Sort by
Items per page

Send to

Choose Destination

Best matches for treatment crohn's disease:

Crohn's disease: a review of treatment options and current research. Bandzar S et al. Cell Immunol. (2013)

Crohn disease: pathophysiology, diagnosis, and treatment. Mazal J et al. Radiol Technol. (2014)

Crohn's disease. Baumgart DC et al. Lancet. (2012)

Search results

Items: 1 to 20 of 26885

1.

Illusions regarding <i>Helicobacter pylori</i> clinical trials and treatment guidelines.

Graham DY.

Gut. 2017 Sep 21. pii: gutjnl-2017-314744. doi: 10.1136/gutjnl-2017-314744. [Epub ahead of print] No abstract available.

PMID:
28935677
2.

Engineered biomimetic nanovesicles show intrinsic anti-inflammatory properties for the treatment of inflammatory bowel diseases.

Corbo C, Cromer WE, Molinaro R, Toledano Furman NE, Hartman KA, De Rosa E, Boada C, Wang X, Zawieja DC, Agostini M, Salvatore F, Abraham BP, Tasciotti E.

Nanoscale. 2017 Sep 21. doi: 10.1039/c7nr04734g. [Epub ahead of print]

PMID:
28932838
3.

The impact of panenteric capsule endoscopy on the management of Crohn's disease.

Eliakim R.

Therap Adv Gastroenterol. 2017 Sep;10(9):737-744. doi: 10.1177/1756283X17720860. Epub 2017 Jul 24. Review.

PMID:
28932274
4.

Ophthalmic manifestations in patients with inflammatory bowel disease: A review.

Troncoso LL, Biancardi AL, de Moraes HV Jr, Zaltman C.

World J Gastroenterol. 2017 Aug 28;23(32):5836-5848. doi: 10.3748/wjg.v23.i32.5836. Review.

PMID:
28932076
5.

Anoperineal lesions in Crohn's disease: French recommendations for clinical practice.

Bouchard D, Abramowitz L, Bouguen G, Brochard C, Dabadie A, de Parades V, Eléouet-Kaplan M, Fathallah N, Faucheron JL, Maggiori L, Panis Y, Pigot F, Rouméguère P, Sénéjoux A, Siproudhis L, Staumont G, Suduca JM, Vinson-Bonnet B, Zeitoun JD.

Tech Coloproctol. 2017 Sep 19. doi: 10.1007/s10151-017-1684-y. [Epub ahead of print] Review.

PMID:
28929282
6.

Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn's Disease.

Luo Y, Yu J, Lou J, Fang Y, Chen J.

Gastroenterol Res Pract. 2017;2017:6595048. doi: 10.1155/2017/6595048. Epub 2017 Aug 8.

PMID:
28928769
7.

Anti-NKG2D mAb: A New Treatment for Crohn's Disease?

Vadstrup K, Bendtsen F.

Int J Mol Sci. 2017 Sep 16;18(9). pii: E1997. doi: 10.3390/ijms18091997. Review.

PMID:
28926962
8.

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.

Gonczi L, Gecse KB, Vegh Z, Kurti Z, Rutka M, Farkas K, Golovics PA, Lovasz BD, Banai J, Bene L, Gasztonyi B, Kristof T, Lakatos L, Miheller P, Nagy F, Palatka K, Papp M, Patai A, Salamon A, Szamosi T, Szepes Z, Toth GT, Vincze A, Szalay B, Molnar T, Lakatos PL.

Inflamm Bowel Dis. 2017 Aug 23. doi: 10.1097/MIB.0000000000001237. [Epub ahead of print]

PMID:
28922253
9.

SHANK3 Regulates Intestinal Barrier Function Through Modulating ZO-1 Expression Through the PKCε-dependent Pathway.

Wei SC, Yang-Yen HF, Tsao PN, Weng MT, Tung CC, Yu LCH, Lai LC, Hsiao JH, Chuang EY, Shun CT, Ni YH, Xavier RJ, Podolsky DK, Yen JJY, Wong JM.

Inflamm Bowel Dis. 2017 Aug 23. doi: 10.1097/MIB.0000000000001250. [Epub ahead of print]

PMID:
28922251
10.

Mesenchymal Stem Cell as a potential therapeutic for inflammatory bowel disease- myth or reality?

Adak S, Mukherjee S, Sen D.

Curr Stem Cell Res Ther. 2017 Sep 13. doi: 10.2174/1574888X12666170914113633. [Epub ahead of print]

PMID:
28914206
11.

Hormonal contraception and the development of autoimmunity: A review of the literature.

Williams WV.

Linacre Q. 2017 Aug;84(3):275-295. doi: 10.1080/00243639.2017.1360065. Epub 2017 Aug 18.

PMID:
28912620
12.

Possible under-treatment of women in Poland with Crohn's disease: a subgroup analysis from a prospective multicenter study of the use of anti-TNFs.

Eder P, Kłopocka M, Wiśniewska-Jarosińska M, Talar-Wojnarowska R, Maj D, Detka-Kowalska I, Kierkuś J, Śliwczyński A, Wieszczy P, Bugajski M, Gonciarz M, Zagórowicz E.

Pol Arch Intern Med. 2017 Aug 31. doi: 10.20452/pamw.4095. [Epub ahead of print] No abstract available.

PMID:
28906483
13.

Can We Predict the Efficacy of Anti-TNF-α Agents?

Lopetuso LR, Gerardi V, Papa V, Scaldaferri F, Rapaccini GL, Gasbarrini A, Papa A.

Int J Mol Sci. 2017 Sep 14;18(9). pii: E1973. doi: 10.3390/ijms18091973. Review.

PMID:
28906475
14.

Secondary Loss of Response to Infliximab in Pediatric Crohn's Disease: Does it Matter How and When We Start?

Bolia R, Rosenbaum J, Schildkraut V, Hardikar W, Oliver M, Cameron D, Alex G.

J Pediatr Gastroenterol Nutr. 2017 Sep 12. doi: 10.1097/MPG.0000000000001742. [Epub ahead of print]

PMID:
28906316
15.

SHANK3 Regulates Intestinal Barrier Function Through Modulating ZO-1 Expression Through the PKCε-dependent Pathway.

Wei SC, Yang-Yen HF, Tsao PN, Weng MT, Tung CC, Yu LCH, Lai LC, Hsiao JH, Chuang EY, Shun CT, Ni YH, Xavier RJ, Podolsky DK, Yen JJY, Wong JM.

Inflamm Bowel Dis. 2017 Oct;23(10):1730-1740. doi: 10.1097/MIB.0000000000001250.

PMID:
28906292
16.

Update on the Therapeutic Efficacy of Tregs in IBD: Thumbs up or Thumbs down?

Fantini MC, Monteleone G.

Inflamm Bowel Dis. 2017 Oct;23(10):1682-1688. doi: 10.1097/MIB.0000000000001272.

PMID:
28906289
17.

IBD LIVE Series-Case 8: Treatment Options for Refractory Esophageal Crohn's Disease and Hidradenitis Suppurativa.

Iskandar H, Greer JB, Krasinskas AM, Tinsley AT, Koltun WA, Siegel CA, Levy LC, Herfarth HH, Farraye FA, Binion DG, Rosh JR, Keljo DJ, Isaacs KL, Regueiro MD.

Inflamm Bowel Dis. 2017 Oct;23(10):1667-1677. doi: 10.1097/MIB.0000000000001266. No abstract available.

PMID:
28906288
18.

Analysis of factors affecting the quality of life of those suffering from Crohn's disease.

Chrobak-Bień J, Gawor A, Paplaczyk M, Małecka-Panas E, Gąsiorowska A.

Pol Przegl Chir. 2017 Aug 31;89(4):16-22. doi: 10.5604/01.3001.0010.3904.

PMID:
28905800
19.

Digestive system in psoriasis: an update.

Pietrzak D, Pietrzak A, Krasowska D, Borzęcki A, Franciszkiewicz-Pietrzak K, Polkowska-Pruszyńska B, Baranowska M, Reich K.

Arch Dermatol Res. 2017 Sep 13. doi: 10.1007/s00403-017-1775-7. [Epub ahead of print] Review.

PMID:
28905102
20.

Butyrate-producing bacteria supplemented in vitro to Crohn's disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity.

Geirnaert A, Calatayud M, Grootaert C, Laukens D, Devriese S, Smagghe G, De Vos M, Boon N, Van de Wiele T.

Sci Rep. 2017 Sep 13;7(1):11450. doi: 10.1038/s41598-017-11734-8.

PMID:
28904372

Supplemental Content

Loading ...
Support Center